This is an archived page. Images and links on this page may not work. Please visit the main page for the latest updates.

Read my book, TEACHING BEAUTY IN DeLILLO, WOOLF, AND MERRILL (Palgrave Macmillan; forthcoming), co-authored with Jennifer Green-Lewis. VISIT MY BRANCH CAMPUS AT INSIDE HIGHER ED

UD is...
"Salty." (Scott McLemee)
"Unvarnished." (Phi Beta Cons)
"Splendidly splenetic." (Culture Industry)
"Except for University Diaries, most academic blogs are tedious."
(Rate Your Students)
"I think of Soltan as the Maureen Dowd of the blogosphere,
except that Maureen Dowd is kind of a wrecking ball of a writer,
and Soltan isn't. For the life of me, I can't figure out her
politics, but she's pretty fabulous, so who gives a damn?"
(Tenured Radical)

Monday, July 02, 2007

AH-C Update:
'Simply Not Willing'

UD has already, on this blog, reported the discovery of the AH gene, predisposing carriers, in the words of the study, "to chronic behavior in an obnoxious, boorish, selfish, overbearing, and generally offensive manner (pp. 128 - 129)."

AH-Carriers have "four alleles... which [we] refer to as rectalleles." Depending on the combination of alleles in carriers, they may be "complete AH's" or lesser varieties of these.

One local high-profile AH-Carrier is sure to catch the attention of researchers:

'A high-powered institute director at the National Institutes of Health disregarded conflict-of-interest guidelines by making decisions affecting the university where he was a faculty member, broke government spending rules, and raised concerns with his growing involvement as an expert witness in legal cases, according to sources within NIH and Congress and hundreds of pages of confidential documents.

[He is] David Schwartz, a physician and researcher recruited from Duke University to great fanfare in 2005 as chief of the National Institute of Environmental Health Sciences...

... In one exchange, when officials learned that Schwartz had not fully divested all his biotechnology and drug company stocks as required, Schwartz wrote to the NIH ethics office that the divestiture "seems totally unreasonable. . . . I'm simply not willing to limit my investments in this way." '